Additionally, in advanced renal cell carcinoma (RCC) where VEGF inhibition has already been standard therapy, a phase III trial (KEYNOTE-426) showed improved outcomes with combination PD1 + VEGF therapy as compared to VEGF inhibition alone [54]. This evidence concerns the gene VEGFA and renal cell carcinoma.